Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06238713

Extraperitoneal SINgle-port rObotic-assisted Radical Prostatectomy (RARP) Versus Transperitoneal Multi-port RARP in the Treatment Of Prostate Cancer (SINO-TOP)

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
480 (estimated)
Sponsor
Shanghai Changzheng Hospital · Academic / Other
Sex
Male
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

This study is a two-arm, multicenter, randomized controlled clinical trial on whether single-port extraperitoneal VIP RARP is non-inferior to multi-port transperitoneal RARP in terms of functional recovery rate and other key metrics.

Detailed description

Multicenter enrollment of 480 patients with localized prostate cancer meeting enrollment criteria are randomized to undergo either single-port robotic extraperitoneal VIP radical prostatectomy or multi-port robotic transperitoneal bilateral intrafascial radical prostatectomy for perioperative data recording, treatment, and monitoring with 1 year follow up.

Conditions

Interventions

TypeNameDescription
PROCEDURESingle-port extraperitoneal robotic-assisted radical prostatectomy with Vattikuti Institute Prostatectomy(VIP) techniquesPatients with localized prostate cancer are randomized into this group in a 1:1 ratio and receive single-port extraperitoneal robotic-assisted radical prostatectomy with Vattikuti Institute Prostatectomy(VIP) techniques. The investigators will monitor patients for perioperative data recording, treatment and 1-year follow-up.
PROCEDUREMulti-port transperitoneal robotic-assisted radical prostatectomy with bilateral intrafascial nerve-sparing techniquesPatients with localized prostate cancer are randomized into this group in a 1:1 ratio and receive multi-port transperitoneal robotic-assisted radical prostatectomy with bilateral intrafascial nerve-sparing techniques. The investigators will monitor patients for perioperative data recording, treatment and 1-year follow-up.

Timeline

Start date
2024-01-08
Primary completion
2025-06-01
Completion
2025-12-01
First posted
2024-02-02
Last updated
2024-08-05

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06238713. Inclusion in this directory is not an endorsement.